LFG
HOWL icon

Larson Financial Group’s Werewolf Therapeutics HOWL Stock Holding History

Larson Financial Group’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.9K Hold
13,052
– – ﹤0.01% 2198
2025
Q4 		$8.27K Buy
13,052
+3,052
+31% +$3.71K ﹤0.01% 2225
2025
Q3 		$19.7K Hold
10,000
– – ﹤0.01% 1655
2025
Q2 		$10.9K Hold
10,000
– – ﹤0.01% 1777
2025
Q1 		$9.72K Hold
10,000
– – ﹤0.01% 1647
2024
Q4 		$14.8K Buy
+10,000
New +$20.4K ﹤0.01% 1337

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Larson Financial Group's HOWL Position: Q1 2026 in Review

Larson Financial Group held its Werewolf Therapeutics (HOWL) position steady in Q1 2026 at 13,052 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2198.

Larson Financial Group first reported a position in HOWL in Q4 2024 and has held it in 6 quarters since. The position peaked at $19.7K in Q3 2025. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Larson Financial Group held 13,052 shares of Werewolf Therapeutics worth $10.9K as of Q1 2026.
  • Larson Financial Group left its Werewolf Therapeutics share count unchanged in Q1 2026.
  • Werewolf Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2198 holding.
  • Larson Financial Group first reported a position in Werewolf Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Larson Financial Group's Werewolf Therapeutics position peaked at $19.7K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.